Abstract
To fully define HLA-A11- restricted HIV-1- specific cytotoxic T-lymphocyte epitopes in China, a method combining the enzyme-linked immunospot (ELISPOT) assay with intracellular gamma interferon staining (ICS) of peripheral blood mononuclear cells (PBMC) was used to map the optimal epitopes targeted by ELISPOT and then to define the HLA restriction of epitopes by ICS. A novel HLA-A11-restricted CTL epitope and five other published HLA-A11-restricted epitopes previously identified by reverse immunogenetics or other methods were defined. The approach of integrating ELISPOT with ICS is both convenient and useful for the characterization of CTL responses to HIV-1 infection; this method is practical for defining novel epitopes and facilitates in developing new strategies for future vaccine design in China and other Asian countries.
Keywords: HIV, cytotoxic T-lymphocyte, epitopes, enzyme-linked immunospot (ELISPOT) assay, intracellular gamma interferon staining (ICS)
Current HIV Research
Title: Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic Tlymphocyte Epitopes in China
Volume: 5 Issue: 1
Author(s): Shaoyang Wang, Yongtao Sun, Song Zhai, Yan Zhuang, Shuguang Zhao, Whenzhen Kang, Xinhong Li, Dedong Huang, Xu G. Yu, Bruce D. Walker and Marcus A. Altfeld
Affiliation:
Keywords: HIV, cytotoxic T-lymphocyte, epitopes, enzyme-linked immunospot (ELISPOT) assay, intracellular gamma interferon staining (ICS)
Abstract: To fully define HLA-A11- restricted HIV-1- specific cytotoxic T-lymphocyte epitopes in China, a method combining the enzyme-linked immunospot (ELISPOT) assay with intracellular gamma interferon staining (ICS) of peripheral blood mononuclear cells (PBMC) was used to map the optimal epitopes targeted by ELISPOT and then to define the HLA restriction of epitopes by ICS. A novel HLA-A11-restricted CTL epitope and five other published HLA-A11-restricted epitopes previously identified by reverse immunogenetics or other methods were defined. The approach of integrating ELISPOT with ICS is both convenient and useful for the characterization of CTL responses to HIV-1 infection; this method is practical for defining novel epitopes and facilitates in developing new strategies for future vaccine design in China and other Asian countries.
Export Options
About this article
Cite this article as:
Wang Shaoyang, Sun Yongtao, Zhai Song, Zhuang Yan, Zhao Shuguang, Kang Whenzhen, Li Xinhong, Huang Dedong, Yu G. Xu, Walker D. Bruce and Altfeld A. Marcus, Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic Tlymphocyte Epitopes in China, Current HIV Research 2007; 5 (1) . https://dx.doi.org/10.2174/157016207779316404
DOI https://dx.doi.org/10.2174/157016207779316404 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Solvent to Sustainable Catalysis - Chloroferrate Ionic Liquids in Synthesis
Current Organic Synthesis Deubiquitinating Enzymes: Their Functions and Substrate Specificity
Current Protein & Peptide Science CAM Use in Pediatric Oncology
Current Pediatric Reviews CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research The Mediating Effect of Different Exercise Programs on the Immune Profile of Frail Older Women with Cognitive Impairment
Current Pharmaceutical Design Modulation of Proinflammatory Bacteria- and Lipid-Coupled Intracellular Signaling Pathways in a Transwell Triple Co-Culture Model by Commensal Bifidobacterium Animalis R101-8
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) In Vitro Evaluation of Bioadhesive Films Containing Ibuprofen
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease
Current Neuropharmacology Autophagy in Invertebrates: Insights Into Development, Regeneration and Body Remodeling
Current Pharmaceutical Design Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome
Current Molecular Medicine Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Inhibitory Action of Andrographolide on Cyclooxygenase-2 Enzyme Activity: In Silico and In Vitro Studies
Current Bioactive Compounds CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Current Gene Therapy Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke
Current Pharmaceutical Design